UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040506
Receipt number R000046239
Scientific Title Cancer gene panel of plasma DNA in patients with solid tumor
Date of disclosure of the study information 2020/05/26
Last modified on 2020/05/25 11:07:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Cancer gene panel of plasma DNA in patients with solid tumor

Acronym

Cancer gene panel of plasma DNA in patients with solid tumor

Scientific Title

Cancer gene panel of plasma DNA in patients with solid tumor

Scientific Title:Acronym

Cancer gene panel of plasma DNA in patients with solid tumor

Region

Japan


Condition

Condition

Solid tumor

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the gene analysis of plasma DNA by NGS in patients with metastatic solid tumor

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Detection rate of somatic gene alterations in plasma DNA

Key secondary outcomes

Detection rate of somatic gene alterations in plasma DNA by cancer type.
Detection rate of somatic gene alterations in plasma DNA by gene.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

110 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Patinets with metastatic solic tumor
2) Age >= 20 years old
3) Patients with tumor harboring gene alteration
4) Written informed consent

Key exclusion criteria

None

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Kenichi
Middle name
Last name Urakami

Organization

Shizuoka Cancer Center Research Institute

Division name

Cancer Diagnostics Research Division

Zip code

411-8777

Address

1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun

TEL

0559895222

Email

k.urakami@scchr.jp


Public contact

Name of contact person

1st name Hirotsugu
Middle name
Last name Kenmotsu

Organization

Shizuoka Cancer Center

Division name

Division of Genetic Medicine Promotion

Zip code

411-8777

Address

1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun

TEL

0559895222

Homepage URL


Email

h.kenmotsu@scchr.jp


Sponsor or person

Institute

Shizuoka Cancer Center

Institute

Department

Personal name



Funding Source

Organization

Shizuoka Cancer Center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shizuoka Cancer Center IRB

Address

1007 Shimonagakubo, Nagaizumi-cho

Tel

0559895222

Email

rinsho_office@scchr.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 05 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2020 Year 05 Month 13 Day

Date of IRB

2020 Year 05 Month 22 Day

Anticipated trial start date

2020 Year 05 Month 27 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

20 mL blood sample will be obtained from patiets emrolled into this study.


Management information

Registered date

2020 Year 05 Month 25 Day

Last modified on

2020 Year 05 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046239


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name